Aardvark Therapeutics target price cut to $2 from $4
AARD•H.C. Wainwright cut its target price for Aardvark Therapeutics to $2 from $4.
Related News
MacroGenics' lorigerlimab shows 25% response rate in Phase 2 clear cell gynecologic cancer trial
MGNX•
Galaxy Digital target price cut to $30 from $35
GLXY•
Stifel initiates coverage of PowerLaw10 with buy rating
PWRL•
Coherent Corp.: StoneX initiates coverage with buy rating; target price $425
COHR•
Tonix Pharmaceuticals to report third-quarter financial results
TNXP•